Clin2
NCT07401121Possibly a fitRecruiting

Study of CTx1000 for people with ALS

ALS (Amyotrophic Lateral Sclerosis)

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests a new drug, CTx1000, for people with ALS. It aims to see if the drug is safe and tolerable, and may offer a new treatment option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
15 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You have been diagnosed with ALS (using specific medical criteria).
  • Your first symptoms started within the last 2 years.
  • You have low or no antibodies against a common virus used in the treatment.
  • You are on stable doses of your ALS medications for at least 30 days before the study starts.
  • You are not pregnant, not breastfeeding, and agree to use birth control.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07660614Recruiting· Phase 1/Phase 2
Testing a new drug for people with ALS

This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.

Lübeck
NCT07287397Recruiting· Phase 1/Phase 2
Testing VTx-002 for safety in ALS patients

This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.

Phoenix, Arizona
NCT07169175Not yet recruiting· Phase 1/Phase 2
Gene therapy trial for early ALS patients

This trial tests a new gene therapy called SNUG01 for adults with ALS. It aims to see if the treatment is safe and can slow the disease. You may be eligible if you are diagnosed early (within 2 years) and have good breathing function.

Boston, Massachusetts
NCT07674667Recruiting· Phase 1/Phase 2
Testing a treatment to restore UNC13A function in ALS

This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.

Munich
NCT06849609Recruiting· Early Phase 1
Gene therapy VGN-R13 for ALS safety and tolerability

This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.

Wuhan, Hubei
NCT06665165Recruiting· Phase 1
Study of AMX0114 for people with ALS

This study tests an experimental drug called AMX0114 for people recently diagnosed with ALS. It is an early-phase trial to see if the drug is safe and how it affects the body.

La Jolla, California

Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.